country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-N10391

Copy Link Print Information

(-)-Cleistenolide

Name: (-)-Cleistenolide
Brand: MedChemExpress
SKU: HY-N10391
Availability: PreOrder

(Synonyms: Cleistenolide)

(-)-Cleistenolide is a α,β-unsaturated δ-lactone isolated from Cleistochlamys kirkii Oliver. (-)-Cleistenolide has antibacterial and antitumor activity.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

CAS No.: 1003600-48-3
Formule: C₁₈H₁₈O₈
Masse moléculaire:362.33

Stockage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (271 KB)

(-)-Cleistenolide Chemical Structure

CAS No.: 1003600-48-3

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- Cellular Effect
- In Vitro
Chemical Information
Protocole (2)
Pureté et documentation
Références
Calculators
Help & FAQs
Classifications
Bioz

Activité biologique

Description

(-)-Cleistenolide is a α,β-unsaturated δ-lactone isolated from Cleistochlamys kirkii Oliver. (-)-Cleistenolide has antibacterial and antitumor activity^[1].

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	16.34 μM Compound: 1	Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 27231128]
A549	IC₅₀	16.34 μM Compound: 1	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 39067378]
HeLa	IC₅₀	7.32 μM Compound: 1	Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 27231128]
HeLa	IC₅₀	7.32 μM Compound: 1	Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 39067378]
HL-60	IC₅₀	1.21 μM Compound: 1	Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 27231128]
HL-60	IC₅₀	1.21 μM Compound: 1	Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 39067378]
Jurkat	IC₅₀	14.22 μM Compound: 1	Cytotoxicity against human Jurkat cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human Jurkat cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 27231128]
Jurkat	IC₅₀	14.22 μM Compound: 1	Antiproliferative activity against human Jurkat cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human Jurkat cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 39067378]
K562	IC₅₀	7.65 μM Compound: 1	Cytotoxicity against human K562 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human K562 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 27231128]
K562	IC₅₀	7.65 μM Compound: 1	Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 39067378]
MCF7	IC₅₀	26.07 μM Compound: 1	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 27231128]
MCF7	IC₅₀	26.07 μM Compound: 1	Antiproliferative activity against estrogen receptor positive human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against estrogen receptor positive human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 39067378]
MDA-MB-231	IC₅₀	2.25 μM Compound: 1	Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 27231128]
MDA-MB-231	IC₅₀	2.25 μM Compound: 1	Antiproliferative activity against estrogen receptor negative human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against estrogen receptor negative human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 39067378]
MRC5	IC₅₀	>100 μM Compound: 1	Cytotoxicity against human MRC5 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 27231128]
MRC5	IC₅₀	>100 μM Compound: 1	Cytotoxicity against human MRC5 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 39067378]
Raji	IC₅₀	36.94 μM Compound: 1	Cytotoxicity against human Raji cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human Raji cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 27231128]
Raji	IC₅₀	36.94 μM Compound: 1	Antiproliferative activity against human Raji cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human Raji cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 39067378]

In Vitro

(-)-Cleistenolide (compound 1) exhibits potent cytotoxicity against cancer cell lines and low cytotoxicity in normal cells MRC-5^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.

Cell Cytotoxicity Assay

View Protocol

Cell Line:

K562, HL-60, Jurkat, Raji, MCF-7, MDA-MB 231, HeLa, A549 and MRC-5^[1]
Concentration:

0-100 μM
Incubation Time:
Result:

Exhibited potent cytotoxicity against cancer cell lines with IC₅₀s of 7.65 μM, 1.21 μM, 14.22 μM, 36.94 μM, 26.07 μM, 2.25 μM, 7.32 μM and 16.34 μM in K562, HL-60, Jurkat, Raji, MCF-7, MDA-MB 231, HeLa and A549, respectively; and had low cytotoxicity in normal cells MRC-5 with an IC₅₀ over 100 μM.

Chemical Information

CAS No. 1003600-48-3
Masse moléculaire 362.33
Formule C₁₈H₁₈O₈
SMILES

CC(O[C@@H]1C=CC(O[C@@H]1[C@H](OC(C)=O)COC(C2=CC=CC=C2)=O)=O)=O
Synonyms

Cleistenolide
Structure Classification
- Ketones, Aldehydes, Acids
Initial Source
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

Please store the product under the recommended conditions in the Certificate of Analysis.

Protocole

All Signal Pathway Related Animals and Diseases

Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (271 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Benedeković G, et al. Synthesis, antiproliferative activity and SAR analysis of (-)-cleistenolide and analogues. Eur J Med Chem. 2020;202:112597. [Content Brief]

Calculators

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Obtenir un devis En stock

Other size

Obtenir un devis